|
KaloBios Shares Slide on Move to Stop Asthma Treatment Study
Wall Street Journal KaloBios Pharmaceuticals Inc.'s (KBIO) shares slumped after the company said it would discontinue development of a treatment for severe asthma, a move that followed disappointing Phase 2 results. Chief Executive Officer David Pritchard said based on … |
View full post on asthma – Google News